1. Almadi MA, Barkun A, Martel M: Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. Am J Gastroenterol. 2017; 112:260-73.
2. Walter D, van Boeckel PG, Groenen MJ, Weusten BL, Witteman BJ, Tan G, et al: Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial. Gastroenterology. 2015; 149:130-8.
3. Moses PL, Alnaamani KM, Barkun AN, Gordon SR, Mitty RD, Branch MS, et al: Randomized trial in malignant biliary obstruction: plastic vs partially covered metal stents. World J Gastroenterol. 2013; 19:8638-46.
4. Soderlund C, Linder S: Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc. 2006; 63:986-95.
5. Katsinelos P, Paikos D, Kountouras J, Chatzimavroudis G, Paroutoglou G, Moschos I, et al: Tannenbaum and metal stents in the palliative treatment of malignant distal bile duct obstruction: a comparative study of patency and cost effectiveness. Surg Endosc. 2006; 20:1587-93.
6. Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, et al: A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc. 1998; 47:1-7.
7. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K: Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992; 340:1488-92.
8. Saleem A, Leggett CL, Murad MH, Baron TH: Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc. 2011; 74:321-27.e1-3.
9. Lee BS, Ryu JK, Jang DK, Chung KH, Yoon WJ, Kim J, et al: Reintervention for occluded metal stent in malignant bile duct obstruction: A prospective randomized trial comparing covered and uncovered metal stent. J Gastroenterol Hepatol. 2016; 31:1901-07.
10. Zhang H, Tsang TK, Jack CA: Bile glycoprotein mucin in sludge occluding biliary stent. J Lab Clin Med. 2003; 142:58-65.
11. Jang S, Stevens T, Parsi MA, Lopez R, Vargo JJ: Aspirin Use Is Associated With Reduced Risk of Occlusion of Metallic Biliary Stents. Clin Gastroenterol Hepatol. 2017; 15:446-53.
12. Galandi D, Schwarzer G, Bassler D, Allgaier HP: Ursodeoxycholic acid and/or antibiotics for prevention of biliary stent occlusion. Cochrane Database Syst Rev. 2002:Cd003043.
13. Lee SP, Carey MC, LaMont JT: Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science. 1981; 211:1429-31.
14. von Ritter C, Niemeyer A, Lange V, Mohrle W, Richter WO, von Meyer L, et al: Indomethacin decreases viscosity of gallbladder bile in patients with cholesterol gallstone disease. Clin Investig. 1993; 71:928-32.
15. Smit JM, Out MM, Groen AK, Huibregtse K, Jansen PL, van Marle J, et al: A placebo-controlled study on the efficacy of aspirin and doxycycline in preventing clogging of biliary endoprostheses. Gastrointest Endosc. 1989; 35:485-9.
16. Rhodes M, Allen A, Dowling RH, Murphy G, Lennard TW: Inhibition of human gall bladder mucus synthesis in patients undergoing cholecystectomy. Gut. 1992; 33:1113-7.
17. Sterling RK, Shiffman ML, Sugerman HJ, Moore EW: Effect of NSAIDs on gallbladder bile composition. Dig Dis Sci. 1995; 40:2220-6.
18. Broomfield PH, Chopra R, Sheinbaum RC, Bonorris GG, Silverman A, Schoenfield LJ, et al: Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med. 1988; 319:1567-72.
19. Sahlin S: Total protein content of human gallbladder bile: relation to cholesterol gallstone disease and effects of treatment with bile acids and aspirin. Eur J Surg. 1996; 162:463-9.
20. Kiriyama S, Takada T, Strasberg SM, Solomkin JS, Mayumi T, Pitt HA, et al: TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2013; 20:24-34.
21. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13:176-81.
22. Yoon WJ, Lee JK, Lee KH, Lee WJ, Ryu JK, Kim YT, et al: A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction. Gastrointest Endosc. 2006; 63:996-1000.
23. Nakai Y, Isayama H, Komatsu Y, Tsujino T, Toda N, Sasahira N, et al: Efficacy and safety of the covered Wallstent in patients with distal malignant biliary obstruction. Gastrointest Endosc. 2005; 62:742-8.
24. Kahaleh M, Tokar J, Conaway MR, Brock A, Le T, Adams RB, et al: Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointest Endosc. 2005; 61:528-33.
25. Zorron Pu L, de Moura EG, Bernardo WM, Baracat FI, Mendonca EQ, Kondo A, et al: Endoscopic stenting for inoperable malignant biliary obstruction: A systematic review and meta-analysis. World J Gastroenterol. 2015; 21:13374-85.
26. Hong WD, Chen XW, Wu WZ, Zhu QH, Chen XR: Metal versus plastic stents for malignant biliary obstruction: an update meta-analysis. Clin Res Hepatol Gastroenterol. 2013; 37:496-500.
27. Lamarca A, Rigby C, McNamara MG, Hubner RA, Valle JW: Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World J Gastroenterol. 2016; 22:6065-75.
28. Lee YN, Moon JH, Choi HJ, Choi MH, Lee TH, Cha SW, et al: Effectiveness of a newly designed antireflux valve metal stent to reduce duodenobiliary reflux in patients with unresectable distal malignant biliary obstruction: a randomized, controlled pilot study (with videos). Gastrointest Endosc. 2016; 83:404-12.
29. Lee TH, Jang BS, Jung MK, Pack CG, Choi JH, Park DH: Fabrication of a silver particle-integrated silicone polymer-covered metal stent against sludge and biofilm formation and stent-induced tissue inflammation. Sci Rep. 2016; 6:35446.
30. Almadi MA, Barkun AN, Martel M: No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol. 2013; 11:27-37.e1.
31. Loew BJ, Howell DA, Sanders MK, Desilets DJ, Kortan PP, May GR, et al: Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. Gastrointest Endosc. 2009; 70:445-53.
32. Seufert BL, Poole EM, Whitton J, Xiao L, Makar KW, Campbell PT, et al: IkappaBKbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis. 2013; 34:79-85.
33. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012; 379:1591-601.
34. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376:1741-50.
35. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al: Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015; 26:47-57.
36. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012; 367:1596-606.
37. Bibbins-Domingo K: Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164:836-45.
38. Leung E, McArthur D, Morris A, Williams N: Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression. Dis Colon Rectum. 2008; 51:342-7.
39. Chen XL, Su BS, Sun RQ, Zhang J, Wang YL: Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma. World J Gastroenterol. 2005; 11:1228-31.
40. Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR: A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res. 2003; 9:383-90.
41. Dibra HK, Brown JE, Hooley P, Nicholl ID: Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. Oncol Rep. 2010; 24:37-46.
42. Najafzadeh M, Normington C, Jacob BK, Isreb M, Gopalan RC, Anderson D: DNA Damage in Healthy Individuals and Respiratory Patients after Treating Whole Blood In vitro with the Bulk and Nano Forms of NSAIDs. Front Mol Biosci. 2016; 3:50.
43. Banti CN, Hadjikakou SK: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Metal Complexes and Their Effect at the Cellular Level. 2016; 2016:3048-71.
44. Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, et al: Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis. Sci Immunol. 2017; 2.
45. Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011; 20:576-90.
46. Baker-Groberg SM, Itakura A, Gruber A, McCarty OJ: Role of coagulation in the recruitment of colon adenocarcinoma cells to thrombus under shear. Am J Physiol Cell Physiol. 2013; 305:C951-9.
47. Lichtenberger LM, Fang D, Bick RJ, Poindexter BJ, Phan T, Bergeron AL, et al: Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. Cancer Prev Res (Phila). 2017; 10:142-52.
48. Reti A, Pap E, Adleff V, Jeney A, Kralovanszky J, Budai B: Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase. Cancer Chemother Pharmacol. 2010; 66:219-27.
49. Cheng Q, Shi H, Wang H, Min Y, Wang J, Liu Y: The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells. Chem Commun (Camb). 2014; 50:7427-30.